16 results about "Specific igg" patented technology

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

The invention relates to the technical field of detection kits, in particular to a milk specificity IgG antibody detection kit which comprises a detection kit body, a storage hole is formed in the bottom end of the detection kit body, the top end of the storage hole is communicated with a discharging cavity, and a feeding pipe fixedly penetrates through the middle of the side face of the detection kit body; the feeding pipe injects a sample solution into the discharging cavity, an extended cleaning mechanism is arranged on the inner wall of the storage hole, the top end of the discharging cavity is communicated with a detection cavity, and a cleaning mechanism, a sampling mechanism and a rotary detection mechanism are arranged on the inner wall of the detection cavity. The extended cleaning mechanism comprises a storage column arranged on the inner wall of the storage hole; the device can ensure that the cleaning scraping plate is continuously and tightly attached to the inner wall of the discharging cavity, the scraping efficiency is guaranteed, the cleaning quality is improved, the cleaning scraping plate can be stored and hidden after cleaning is completed, deformation caused by collision with a sampling rod during sampling is avoided, and the cleaning performance of the cleaning scraping plate is maintained.

Provided are an RSV F protein mutant, and a preparation method therefor and a use thereof. Provided is a mutant protein, the mutant protein being in the form of a monomer or a trimer, wherein the trimer is formed by three monomeric mutant proteins; the monomeric mutant protein is a fusion protein comprising a first polypeptide element derived from an RSV F protein and a trimerization domain element; in the first polypeptide element, a Pep27 fragment of the RSV F protein is replaced with a linker sequence; and the monomeric and trimeric mutant proteins are both bound by an antibody that specifically recognizes RSV pre-F. The mutant protein can stably remain in a pre-fusion state, can induce the production of specific IgG antibodies and neutralizing antibodies, has excellent immunogenicity, and can be used for the development of RSV vaccines.

An agent including a glycan-specific IgG antibody moiety, a cellular receptor binding moiety which binds to hepatocytes or other degrading cells through asialoglycoprotein (ASGPR) receptors of hepatocytes or other cell receptors which are on the surface degrading cells in a patient or subject, and optionally, a linker moiety connecting the glycan-specific IgG antibody moiety and the cellular receptor binding moiety.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The present application belongs to the field of biomedical technology, and more particularly relates to the application of Periplaneta americana polypeptide HFDT1 as an immune adjuvant in the preparation of a brucellosis vaccine. The present application uses Brucella OMP10, BP26 and L7 / L12 proteins in combination with HFDT1 to induce mice to produce higher titers of anti-OMP10, BP26 and L7 / L12 protein specific IgG antibodies, and the titers increase with the increase in the number of immunizations, while promoting the body to produce mixed Th1 / Th2 type cellular immune responses and stimulating the proliferation and differentiation of mouse spleen T and B cells, and also facilitating mass production. The Periplaneta americana polypeptide HFDT1 described in the present application is obtained by convenient mass synthesis, and can be used as a novel small molecule immune adjuvant to enhance specific immune responses of the body.

This invention relates to the field of biomedical technology, specifically disclosing a three-component recombinant subunit vaccine composition for Mycoplasma pneumoniae and its application. The vaccine composition comprises key antigenic proteins of Mycoplasma pneumoniae (MP): P1 protein, P40 / 90 protein, and an E132A attenuated mutant of community-acquired respiratory distress syndrome (CARDS) toxin (CARDS-Mut), optionally combined with Al(OH)3 single adjuvant or Al(OH)3+CPG double adjuvant. The recombinant protein was successfully purified using a prokaryotic expression system, and validated in a mouse model. The vaccine induces high-titer specific IgG antibodies, significantly alleviates lung tissue pathological damage, reduces bacterial load, and inhibits inflammatory factor secretion after challenge, with good safety. This invention solves the problem of high toxicity of CARDS toxin, providing an efficient and safe vaccine strategy for the prevention and control of MP infection.

The present invention belongs to the technical field of biomedicine, and specifically relates to a recombinant influenza virus protein, a vaccine, and a preparation method therefor and the use thereof. To overcome the defects of existing influenza vaccines with respect to safety and high toxic side effects, a recombinant influenza virus protein is provided, which has an amino acid sequence as shown in at least one of SEQ ID No. 1 to SEQ ID No. 6. Recombinant hemagglutinin proteins of H1N1 and H3N2 subtypes, and Victoria and Yamagata lineages are expressed and purified by means of an insect baculovirus expression system, and are mixed with an adjuvant to prepare a highly immunogenic recombinant bivalent, trivalent or quadrivalent recombinant influenza virus protein vaccine. The prepared vaccine can induce high levels of specific IgG antibodies and hemagglutination-inhibiting neutralizing antibodies, the addition of adjuvant WGa01 improves the immunogenicity of the vaccine, and the provided vaccine is suitable for people allergic to eggs and has high safety.

The invention belongs to the technical field of biological detection, and discloses a food specific IgG antibody detection reagent card, a food specific IgG antibody detection kit, a preparation method and application. The food specific IgG antibody detection reagent card prepared by the preparation method can qualitatively detect and analyze the specific IgG antibody in human serum or fingertip whole blood based on immunochromatography. The kit prepared from the reagent card is used for detecting the food specific IgG antibody, has the characteristics of high detection sensitivity, strong specificity, simplicity in operation, cost saving and the like, and has a great market and a good application prospect.

The invention discloses a canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine and a preparation method thereof, and relates to the technical field of biological medicines. The canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine takes recombinant proteins rEg 05752 and rEg 09809 as core double antigens, and the recombinant proteins rEg 05752 and rEg 09809 do not have transmembrane regions and signal peptides and contain a plurality of B cell antigen epitopes. After a beagle is immunized, a body can be efficiently induced to generate a specific IgG antibody, the titer of the antibody reaches a peak value 35 days after immunization and still maintains a relatively high level after attack, and meanwhile, Th1 / Th2 type mixed immune response is remarkably activated, so that the levels of cell factors such as IL-2, IFN-gamma, IL-4 and IL-5 are greatly improved. The immune protection effect is remarkable, and a safe and efficient novel technical means is provided for source prevention and control of the cystic echinococcosis.

The invention discloses a bovine parainfluenza virus 3A and 3C type multi-epitope antigen peptide as well as a compound and application thereof. The amino acid sequences of the multi-epitope antigen peptides BPIV-3A and BPIV-3C are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 3, and the multi-epitope antigen peptides are formed by connecting CTL epitopes, HTL epitopes and B cell epitopes screened from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immune tests show that the antigen peptide and the compound thereof can effectively stimulate a body to generate a specific IgG antibody and a neutralizing antibody, induce immune response of Th1 type cells, effectively eliminate viruses and relieve lung tissue lesions, and show good immunogenicity and protection effect. The invention provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The invention relates to the technical field of biological medicines, in particular to a mycoplasma hyopneumoniae extracellular vesicle, a vaccine and a preparation method and application of the mycoplasma hyopneumoniae extracellular vesicle. The diameter of the mycoplasma hyopneumoniae extracellular vesicles ranges from 120 nm to 220 nm, and the mycoplasma hyopneumoniae extracellular vesicles are extracted from a mycoplasma hyopneumoniae culture. The mycoplasma hyopneumoniae extracellular vesicle provided by the invention is used for preventing mycoplasma hyopneumoniae infection after being used as a vaccine for immunization, reducing the lung lesion index and reducing the tissue pathogen load; the pig body can be induced to generate specific IgG antibodies, sIgA antibodies, IFN-gamma and IL-17 cell factors, and peripheral blood and lung mononuclear cell proliferation can be stimulated.

This invention discloses the application of β-Hordothionin, its active fragment, or derivatives as intramolecular adjuvants, specifically involving a polypeptide derived from β-Hordothionin, the amino acid sequence of which is shown in SEQ ID NO.1, and the polynucleotide sequence of which is shown in SEQ ID NO.2. The polypeptide is fused with the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and expressed, significantly enhancing the immunogenicity of the antigen. Experiments show that immunization of mice with the RBD-β-Hordothionin fusion protein induces a 1000-fold increase in specific IgG antibody titers compared to the RBD antigen alone. This fusion protein can be industrially prepared and can be used to enhance the immunogenicity of vaccine antigens.

The invention provides a method for detecting a specific IgG antibody in SD rat serum, and belongs to the technical field of biological detection. The detection method special for the SD rat serum sample is established, the operation process is standard, the result is stable and reliable, matrix interference can be effectively eliminated, and specific recognition and detection of a target antibody are achieved; the application of the method provides key technical support for preclinical efficacy and immunogenicity evaluation of related biopharmacy, significantly improves the accuracy and comparability of experimental data, and has positive significance in promoting the research and development process of drugs.

The invention discloses application of Macranthoidin B in a vaccine adjuvant, relates to application of Macranthoidin B, and belongs to the technical field of biological medicines. The invention mainly aims at providing a brand new application of the Macranthoidin B, namely the application of the Macranthoidin B in preparation of a vaccine adjuvant. The invention provides an application of Macranthoidin B in preparation of a vaccine adjuvant. The Macranthoidin B is used as an active component of a vaccine adjuvant in the vaccine composition. When the Macranthoidin B is combined with a protein antigen (ovalbumin) for use, the Macranthoidin B can induce to generate adaptive immune responses which are obviously better than reference adjuvants QS-21 and R848, and the adaptive immune responses comprise higher-level antigen-specific IgG, more antigen-specific memory B cells and stronger antigen-specific T cell reactions. Meanwhile, the Macranthoidin B does not cause obvious hepatotoxicity in an effective dose, and has better safety. The invention provides a new candidate compound for developing an efficient and safe vaccine adjuvant.

Developing an effective HIV-1 vaccineis contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, vaccine candidates such as LC3.SOSIP(w) and LC3.SOSIP(s) showed promising results in New Zealand white rabbits. These candidates elicited significantly higher Env-specific IgG levels than controls, demonstrated high affinity for SOSIP antigens in ELISA binding assays, and achieved broad neutralizing capabilities against multiple HIV-1 pseudoviruses in TZM-bl neutralization assays. In conclusion, HIV Env antigen can be adaptively targeted to LC as a trimer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such constructs as LC targeting HIV-1 vaccines.